title: Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
abstract: In addition to nausea and vomiting, motion sickness involves slowing of brain waves, loss of performance, inhibition of gastric motility and the Sopite Syndrome. The therapeutic effects of antimotion sickness drugs on these reactions were evaluated. The subjects were rotated to the M-III end-point of motion sickness. Intramuscular (IM) medications were then administered. Side effects before and after rotation were reported on the Cornell Medical Index. Brain waves were recorded on a Grass Model 6 Electroencephalograph (EEG), and gastric emptying was studied after an oral dose of 1 mCi Technetium 99m DTPA in 10 oz. isotonic saline. An increase in dizziness and drowsiness was reported with placebo after rotation. This was not prevented by IM scopolamine 0.1 mg or ephedrine 25 mg. EEG recordings indicated a slowing of alpha waves with some thea and delta waves from the frontal areas after rotation. IM ephedrine and dimenhydrinate counteracted the slowing while 0.3 mg scopolamine had an additive effect. Alterations of performance on the pursuit meter correlated with the brain wave changes. Gastric emptying was restored by IM metoclopramide. Ephedrine IM but not scopolamine is effective for some of the secondary effects of motion sickness after it is established.
authors.affiliation: Louisiana State University Medical Center, Department of Pharmacology, Shreveport 71130-3932.
authors.forename: C D
authors.initials: CD
authors.lastname: Wood
authors.forename: J J
authors.initials: JJ
authors.lastname: Stewart
authors.forename: M J
authors.initials: MJ
authors.lastname: Wood
authors.forename: J E
authors.initials: JE
authors.lastname: Manno
authors.forename: B R
authors.initials: BR
authors.lastname: Manno
authors.forename: M E
authors.initials: ME
authors.lastname: Mims
mesh_terms: D000293:Adolescent; D000328:Adult; D001143:Arousal / Q000187:drug effects*; D002110:Caffeine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005934:Glucagon / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage*; D009041:Motion Sickness / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012601:Scopolamine / Q000008:administration & dosage*; D012815:Signal Processing, Computer-Assisted; D013026:Space Flight; D013577:Syndrome
chemical_list: D002110:Caffeine; D005934:Glucagon; D012601:Scopolamine; D008787:Metoclopramide